

These articles have been accepted for publication in the *British Journal of Dermatology* and are currently being edited and typeset. Readers should note that articles published below have been fully refereed, but have not been through the copy-editing and proof correction process. Wiley-Blackwell and the British Association of Dermatologists cannot be held responsible for errors or consequences arising from the use of information contained in these articles; nor do the views and opinions expressed necessarily reflect those of Wiley-Blackwell or the British Association of Dermatologists

Accepted Date : 20-Dec-2011

Article type : Item of Correspondence

Granulomatous foreign-body reaction with facial dermal fillers after omalizumab treatment
for severe persistent allergic asthma: a case report

A. Dammak,¹ C. Taillé,² E. Marinho,³ B. Crestani,² B. Crickx,¹ V. Descamps¹

Address

Department of Dermatology

Bichat Claude Bernard Hospital

46 rue Henri Huchard

75877 Paris Cedex 18

¹ Université Paris Diderot, Service de Dermatologie, Paris ; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Hôpitaux Universitaires Paris Nord Val de Seine, Paris

² Université Paris Diderot, Service de Pneumologie et Centre de Compétence des Maladies Pulmonaires Rares, Paris ; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Hôpitaux Universitaires Paris Nord Val de Seine, Paris ; INSERM U700, Paris, France.

¹ Service d'Anatomopathologie, Paris ; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Hôpitaux Universitaires Paris Nord Val de Seine, Paris

Correspondence: Vincent Descamps

Email: vincent.descamps@bch.aphp.fr

Abstract:

Complications with the increased use of dermal fillers and new therapies with immunomodulatory effects may be increasing. We report on a 50-year-old woman who presented disfiguring facial edema 1 month after the initiation of omalizumab treatment for severe persistent allergic asthma. She had received multiple cosmetic filler injections, including hyaluronic acid and calcium hydroxylapatite, for 4 years without any previous side effects. A biopsy of a lip nodule revealed a foreign-body granulomatous reaction. Treatment was with high-dose prednisone and doxycycline, with clinical improvement.

As was previously reported with interferon, foreign-body granulomatous reaction may occur with omalizumab treatment after dermal filler injections.

During the last few decades, an increasing number of soft-tissue filler substances have been introduced to the beauty market worldwide for treating age wrinkles, correcting atrophic scars or small cutaneous defects, and cosmetically augmenting soft tissue of different parts of the body [1]. Although these injectable fillers are considered safe, significant adverse reactions may occur [2]. As was reported with α -interferon, new immunomodulatory therapies used for inflammatory and allergic disease may produce a foreign-body granulomatous reaction in patients injected with dermal fillers [3].

We report on a case of a patient who had received hyaluronic acid (HA) and calcium hydroxylapatite injections and showed foreign-body granulomatous reaction after omalizumab administration for severe persistent allergic asthma.

A 50-year-old Caucasian woman with facial erythematous nodules was referred to our clinic. She had received treatment for adult-onset severe allergic asthma with maximal inhaled corticosteroids and montelukast, but the asthma remained poorly controlled, with frequent exacerbations requiring monthly courses of oral steroids. A 16-week trial treatment with omalizumab (300 mg subcutaneously/month) was started. The last short course of oral steroids for an exacerbation was stopped 10 days before the first administration of omalizumab.

Edema, first localized on the eyelids, appeared 2 weeks after the first administration of omalizumab and disappeared after application of a topical steroid. The facial edema recurred after the second monthly injection, but was more extensive and persisted. The patient had blue-red swelling mainly on the eyelids and upper and lower lips (Fig. 1). On palpation, these nodules were painful and moved but were not well defined. Neither fever nor lymphadenopathy was noted.

The patient had received annual cosmetic filler injections in the nasolabial folds, lips and eyelids since 2006. The dermal fillers were HA in 2006, 2008, and 2009, and calcium hydroxylapatite in 2008.

Results were normal for all laboratory tests, including serum chemistry, complete blood cell count, erythrocyte sedimentation rate and levels of angiotensin-converting enzyme and C-reactive protein. Histopathological examination of a lip nodule by a 4-mm punch biopsy revealed a foreign-body granulomatous reaction at the dermal-subcutaneous fat border that was composed of histiocytic cells and lymphocytes surrounding densely packed, small, round cystic spaces that contained translucent, non-birefringent, uniformly sized microspheres (Fig. 2). The patient received prednisone (1 mg/kg/day) for 15 days with gradual reduction of the dose, combined with doxycycline (100 mg/day) for 3 months. Despite improvement in asthma control with the first omalizumab injection, omalizumab withdrawal was decided. Clinical improvement was noted after 2 weeks of oral steroid treatment. Further improvement was noted at 8 months, but fibrous nodules were still palpable.

Omalizumab is considered a safe and well-tolerated treatment for asthma. However, several cases of Churg–Strauss syndrome have been reported with the treatment in patients with severe eosinophilic asthma [4]. To the best of our knowledge, our case is the first report of a foreign-body granulomatous response with dermal filler injection after omalizumab treatment. Our histological findings suggest that the granulomatous reaction was mainly due to calcium hydroxylapatite microspheres. Only a few macrophages were observed around the particles, and the microspheres appeared to be packed together, had a round or oval shape, and were surrounded by some fibrin fibres, with little cellular infiltrate [5]. Granulomas develop from delayed hypersensitivity phenomenon. The induction of dermal-filler granuloma by an immunomodulatory drug has been observed with interferon treatment [3]. Interferon may

induce systemic sarcoidosis, especially in patients with chronic hepatitis C. Dermal fillers may be a target in the interferon-induced granulomatous reaction.

Omalizumab is a monoclonal anti-IgE antibody which reduces exacerbations and the need for inhaled or systemic corticosteroids for patients with moderate to severe allergic asthma [6,7]. The inflammatory granulomatous facial reaction occurred only 2 weeks after the first omalizumab injection. We cannot exclude that frequent use of systemic corticosteroid treatment could have masked the foreign-body granulomatous reaction in our case, but the rapid and enhanced development of this reaction after omalizumab initiation, as well as the worsening after the second administration, suggests the direct responsibility of omalizumab. A deviation of immunity from T helper 2 (Th2) to Th1 cells may explain the granulomatous reaction as proposed in interferon-induced granuloma [3]. Rapid reduction in systemic steroid use may participate in this process, as was reported for Churg–Strauss syndrome masked by long-term corticosteroid treatment [4].

Clinicians and patients must be aware of the risk of foreign-body granulomatous reactions after omalizumab treatment. In the same way that we think that dermatologists must inform patients who may receive α -interferon of the risk of any filler injection and may exclude them, asthmatic patients who are candidate for omalizumab treatment should also receive this information. Before initiation of omalizumab treatment for asthma, patients should be asked about previous use of dermal fillers, and patients with dermal fillers must be monitored during omalizumab administration, especially when steroid use can be reduced.

Contributions: Laura Smales, heraty1@gmail.com, proofread the manuscript.

References

- 1- Rivkin A. New fillers under consideration: what is the future of injectable aesthetics? *Facial Plast Surg.* 2009;25:120-3.
- 2- Requena L, Requena C, Christensen L, Zimmermann US, Kutzner H, Cerroni L. Adverse reactions to injectable soft tissue fillers. *J Am Acad Dermatol.* 2011;64:1-34.
- 3- Descamps V, Landry J, Frances C, Marinho E, Ratzu V, Chosidow O. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. *Dermatology* 2008;217:81-4.
- 4- Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. *Chest.* 2009;136:507-18.
- 5- Drobeck HP, Rothstein SS, Gumaer KI, Sherer AD, Slighter RG. Histologic observation of soft tissue responses to implanted, multifaceted particles and discs of hydroxylapatite. *J Oral Maxillofac Surg* 1984;42:143-9.
- 6- Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Della Cioppa G, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol* 2001;108:184e90.
- 7- Chipps B, Buhl R, Beeh K-M, Fox H, Thomas K, Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. *Curr Med Res Opin* 2006;22:2201- 8.

FIGURE LEGENDS:

Figure 1: Inflammatory facial edema after the second monthly omalizumab administration for severe persistent allergic asthma in a 50-year-old woman who had received multiple cosmetic filler injections for 4 years without previous side effects.

Figure 2: Histology of a skin nodule showing foreign-body granulomatous reaction composed of histiocytic cells and lymphocytes surrounding small, round microspheres after to omalizumab administration.



